Search results for "thromboembolism"

showing 10 items of 208 documents

Lipoprotein(a) is not associated with venous thromboembolism risk.

2020

Objectives. Evidence from case-control studies as well as meta-analyses of these study designs suggest elevated lipoprotein(a) [Lp(a)] to be associated with an increased risk of venous thromboembolism (VTE). Prospective evidence on the association is limited, uncertain, and could be attributed to regression dilution bias. We aimed to assess the prospective association of Lp(a) with risk of VTE and correct for regression dilution. Design. We related plasma Lp(a) concentrations to the incidence of VTE in 2,180 men of the Kuopio Ischemic Heart Disease cohort study. Hazard ratios (HRs) (95% confidence intervals [CI]) were assessed and repeat measurements of Lp(a) at 4 and 11 years from baseline…

AdultMalemedicine.medical_specialtyTime FactorsPopulationRegression dilutionvenous thromboembolism030204 cardiovascular system & hematologyRisk Assessment03 medical and health sciences0302 clinical medicineRisk FactorsInternal medicinemedicinecohort studyHumans030212 general & internal medicineregression dilutionProspective StudiesRisk factoreducationFinlandeducation.field_of_studybiologybusiness.industryIncidenceHazard ratioConfoundingLipoprotein(a)Venous ThromboembolismMiddle AgedPrognosisConfidence intervalrisk factorbiology.proteinCardiology and Cardiovascular MedicinebusinessBiomarkersCohort studyLipoprotein(a)Scandinavian cardiovascular journal : SCJ
researchProduct

Pulmonary embolism location is associated with the co-existence of the deep venous thrombosis.

2019

Multiple studies have shown that in approximately half of individuals with pulmonary embolism (PE), the deep venous thrombosis (DVT) is not evident at the moment of PE diagnosis. The underlying factors and the origin of PE in these patients are not completely understood: missed DVT, embolization of DVT in its entirety, or de-novo PE being possible explanations. The aim of this study was to evaluate the differences in PE patient with or without co-existing DVT. Sixty-three consecutive PE patients were included. Whole leg bilateral Doppler compression ultrasound was performed to all patients. The PE location and extension, C-reactive protein, platelet count, hemostatic markers FV, FVIII, FXII…

AdultMalemedicine.medical_specialtyVEIN THROMBOSISmedicine.medical_treatment030204 cardiovascular system & hematologyFibrinogenPulmonary function testing03 medical and health sciencesTHROMBOEMBOLISM0302 clinical medicineInternal medicineSCOREmedicineFactor V LeidenFACTOR-V-LEIDENHumanscardiovascular diseasesEmbolizationProspective Studiescoagulationhemostatic markersProspective cohort studydeep venous thrombosisAgedRISKVenous ThrombosisHemostasisLegbusiness.industryUltrasonography DopplerHematologyGeneral MedicineNITRIC-OXIDE MEASUREMENTSMiddle Agedmedicine.disease3. Good healthPulmonary embolismVenous thrombosis3121 General medicine internal medicine and other clinical medicineHemostasisisolated pulmonary embolismCardiologyFemalebusinessPulmonary Embolism030215 immunologymedicine.drugBlood coagulationfibrinolysis : an international journal in haemostasis and thrombosis
researchProduct

Residual vein thrombosis for assessing duration of anticoagulation after unprovoked deep vein thrombosis of the lower limbs: the extended DACUS study.

2011

Abstract The safest duration of anticoagulation after idiopathic deep vein thrombosis (DVT) is unknown. We conducted a prospective study to assess the optimal duration of vitamin K antagonist (VKA) therapy considering the risk of recurrence of thrombosis according to residual vein thrombosis (RVT). Patients with a first unprovoked DVT were evaluated for the presence of RVT after 3 months of VKA administration; those without RVT suspended VKA, while those with RVT continued oral anticoagulation for up to 2 years. Recurrent thrombosis and/or bleeding events were recorded during treatment (RVT group) and 1 year after VKA withdrawal (both groups). Among 409 patients evaluated for unprovoked DVT…

AdultMalemedicine.medical_specialtyVitamin Kmedicine.drug_classDeep veinHemorrhageDrug Administration ScheduleSettore MED/15 - Malattie Del SangueRecurrenceRisk Factorsdeep vein thrombosis (DVT)Residual vein thrombosismedicineHumansProspective Studiesdeep vein thrombosis (DVT); vitamin K antagonist (VKA) therapy; Residual vein thrombosisProspective cohort studyAgedUltrasonographyVenous Thrombosisbusiness.industryAcenocoumarolAnticoagulantsHematologyVenous ThromboembolismVitamin K antagonistMiddle Agedmedicine.diseaseThrombosisConfidence intervalSurgeryClinical trialVein thrombosisvitamin K antagonist (VKA) therapymedicine.anatomical_structureLower ExtremityRelative riskFemaleWarfarinbusiness
researchProduct

Residual vein obstruction in patients diagnosed with acute isolated distal deep vein thrombosis associated with active cancer.

2018

After acute proximal deep vein thrombosis (DVT) the thrombotic mass decreases, especially during the first months of anticoagulation. The persistence of residual vein obstruction (RVO) may predict future recurrence in patients with cancer-associated DVT. We aimed to evaluate the proportion of patients with RVO after an episode of cancer associated isolated distal DVT (IDDVT), to identify variables associated with RVO, and to provide initial evidence of its association with recurrent VTE. We performed a post-hoc analysis of a multicenter cohort study of patients with isolated cancer-associated acute IDDVT. We included patients who underwent a control ultrasonography at the end of the anticoa…

AdultMalemedicine.medical_specialtymedicine.drug_classDeep vein030204 cardiovascular system & hematologyCompression ultrasound; Distal deep vein thrombosis; Recurrence; Residual vein obstruction; Venous thromboembolism; Hematology; Cardiology and Cardiovascular Medicine03 medical and health sciences0302 clinical medicineRecurrenceRisk FactorsInternal medicineNeoplasmsmedicineHumansIn patientDistal deep vein thrombosiAgedUltrasonographyVenous ThrombosisHematologybusiness.industryRisk FactorAnticoagulantAnticoagulantCancerAnticoagulantsHematologyVenous ThromboembolismCompression ultrasoundMiddle Agedmedicine.diseaseThrombosisSurgeryDiscontinuationmedicine.anatomical_structureDistal deep vein thrombosis030220 oncology & carcinogenesisResidual vein obstructionAcute DiseaseNeoplasmFemalebusinessCardiology and Cardiovascular MedicineHumanCohort studyJournal of thrombosis and thrombolysis
researchProduct

Predictive value of venous thromboembolism (VTE)-BLEED to predict major bleeding and other adverse events in a practice-based cohort of patients with…

2018

Summary Venous thromboembolism (VTE)‐BLEED, a decision tool for predicting major bleeding during chronic anticoagulation for VTE has not yet been validated in practice‐based conditions. We calculated the prognostic indices of VTE‐BLEED for major bleeding after day 30 and day 90, as well as for recurrent VTE and all‐cause mortality, in 4457 patients enrolled in the international, prospective XALIA study. The median at‐risk time was 190 days (interquartile range 106–360). The crude hazard ratio (HR) for major bleeding after day 30 was 2·6 [95% confidence interval (CI) 1·3–5·2] and the treatment‐adjusted HR was 2·3 (95% CI 1·1–4·5) for VTE‐BLEED high (versus low) risk patients: the correspondi…

AdultMalemedicine.medical_specialtyvenous thromboembolismHemorrhage030204 cardiovascular system & hematologyDisease-Free Survival03 medical and health sciencesYoung Adult0302 clinical medicineInterquartile rangePredictive Value of TestsInternal medicinemedicineanticoagulation therapy; bleeding; prediction; rivaroxaban; venous thromboembolism; HematologyHumans030212 general & internal medicinecardiovascular diseasesProspective StudiesAdverse effectrivaroxabanRivaroxabananticoagulation therapybusiness.industryIncidence (epidemiology)Platelets Haemostasis and ThrombosisHazard ratioHematologypredictionBleedMiddle Agedequipment and suppliesbleedingConfidence intervalddc:Survival RateCohortFemalebusinessmedicine.drugResearch Paper
researchProduct

Thigh-length versus below-knee compression elastic stockings for prevention of the postthrombotic syndrome in patients with proximal-venous thrombosi…

2012

Abstract Although below-knee compression elastic stockings (CES) are effective for the prevention of the postthrombotic syndrome (PTS), a substantial number of patients with deep venous thrombosis still develop PTS. In the present open-label, randomized clinical trial, we compared thigh-length with below-knee CES for the prevention of PTS. A total of 267 patients with the first episode of proximal deep venous thrombosis were randomized to wear either thigh-length or below-knee CES for 2 years. After 3, 6, 12, 18, 24, and 36 months, they were assessed for PTS manifestations according to the Villalta scale. PTS developed in 44 (32.6%) of the 135 patients randomized to thigh-length CES and in …

AdultMalemusculoskeletal diseasesmedicine.medical_specialtyTime FactorsImmunologyThighbehavioral disciplines and activitiesBiochemistryPostthrombotic SyndromeSettore MED/15 - Malattie Del Sanguelaw.inventionPOST-THROMBOTIC SYNDROMEYoung AdultRandomized controlled triallawmedicineHumansKneeAgedAged 80 and overVenous ThrombosisFirst episodeVENOUS THROMBOEMBOLISMbusiness.industryPruritusHazard ratioCell BiologyHematologyMiddle Agedmusculoskeletal systemmedicine.diseaseThrombosishumanitiesConfidence intervalDiscontinuationSurgeryVenous thrombosisTreatment Outcomemedicine.anatomical_structureThighErythemaPatient ComplianceFemalevenous thrombosisbusinessStockings CompressionFollow-Up StudiesBlood
researchProduct

Thromboembolic events in patients with influenza. A scoping review.

2022

Introduction: Influenza is an acute respiratory infection that usually causes a short-term and self-limiting illness. However, in high-risk populations, this can lead to several complications, with an increase in mortality. Aside from the well-known extrapulmonary complications, several studies have investigated the relationship between influenza and acute cardio and cerebrovascular events. Reviews of the thromboembolic complications associated with influenza are lacking. Objectives: the study aims to conduct a scoping review to analyze the epidemiological and clinical characteristics of patients suffering from influenza and thromboembolic complications. Materials and methods: A computerize…

AdultVenous ThrombosisInfectious DiseasesVirologyThromboembolismflu infarct influenza stroke thromboembolism thrombosisHumansThrombosisChildPulmonary EmbolismIschemic Stroke
researchProduct

Primary thromboprophylaxis for adult patients on home parenteral nutrition: A comment on the 2016 ESPEN guideline

2016

AdultVenous ThrombosisParenteral Nutritionmedicine.medical_specialtyNutrition and DieteticsAdult patientsbusiness.industryAnticoagulantsVenous ThromboembolismGuideline030204 cardiovascular system & hematologyCritical Care and Intensive Care Medicinemedicine.diseaseThrombosis03 medical and health sciencesVenous thrombosis0302 clinical medicineParenteral nutritionmedicineHumans030211 gastroenterology & hepatologyParenteral Nutrition HomeIntensive care medicinebusinessVenous thromboembolism
researchProduct

Topical Issues in Venous Thromboembolism

2010

Despite clear guidelines and the availability of effective treatments, venous thromboembolism (VTE) remains relatively common, particularly in the hospital setting. This paper reviews topical issues in VTE, in terms of treatments, data and guidelines. Existing anticoagulants have several limitations. Bleeding risk is a concern with all anticoagulants. Vitamin K antagonists are the mainstay of oral anticoagulant therapy, but they are limited by the need for frequent monitoring. Unfractionated heparin (UFH) is limited by an inconvenient route of administration (continuous intravenous infusion) and a higher risk of heparin-induced thrombocytopenia and bleeding compared with low molecular weigh…

Adultmedicine.medical_specialtyBlood Loss SurgicalVenographyFondaparinuxRoute of administrationPharmacotherapymedicineHumansPharmacology (medical)DosingChildIntensive care medicineSocieties Medicalmedicine.diagnostic_testbusiness.industryAnticoagulantsVenous ThromboembolismHeparinmedicine.diseaseUnited StatesClinical trialVenous thrombosisClinical AlarmsPractice Guidelines as TopicDrug Monitoringbusinessmedicine.drugDrugs
researchProduct

Evaluation of the Stratus® CS Acute Care™ D-dimer assay (DDMR) using the Stratus® CS STAT Fluorometric Analyzer: A prospective multisite study for ex…

2012

Abstract Background D-dimer testing is an integral part of the diagnostic algorithm in excluding patients with venous thromboembolism. In this study, we prospectively evaluated the Stratus DDMR D-dimer test in patients suspected of pulmonary embolism (PE) and deep vein thrombosis (DVT). Methods Patients suspected of venous thromboembolism were prospectively enrolled at four different clinical sites, with sodium citrate and lithium heparin plasma was tested using the DDMR D-dimer test on the Stratus CS analyzer. Results 1,012 patients were enrolled for analysis, with 85/603 (14.1%) patients with PE and 80/443 (18.1%) with DVT, and four of the patients (0.4%) with PE and DVT. For the samples …

Adultmedicine.medical_specialtyDeep veinGastroenterologyD-dimer assayFibrin Fibrinogen Degradation ProductsYoung AdultInternal medicineAcute caremedicineHumansFluorometryProspective Studiescardiovascular diseasesProspective cohort studyAgedAged 80 and overImmunoassayVenous Thrombosisbusiness.industryHematologyHeparinMiddle Agedmedicine.diseaseThrombosisPulmonary embolismSurgerymedicine.anatomical_structurePulmonary EmbolismbusinessVenous thromboembolismmedicine.drugThrombosis Research
researchProduct